February 23, 2021 -- Medical simulation software company Simulations Plus and the University of Pittsburgh Drug Discovery Institute (UPDDI) have jointly received a phase I grant from the U.S. National Institutes of Health (NIH)-funded Small Business Innovation Research (SBIR) grant to support their large-molecule safety collaboration.
As a result of the funding from the NIH, Simulation Plus' Dilisym Services (DSS) division will combine its software with UPDDI's biomimetic human liver microphysiological systems (vLAMPS) experimental liver model and the microphysiology systems database to predict the safety of large molecules such as proteins for treating diseases.
In the first phase of the project, a beta version of software will be constructed and vLAMPS testing will be performed for several large molecules captured in the database. If the objectives are successfully completed, Simulation Plus and UPDDI will then apply for a larger phase II grant to fully fund development of a joint commercial offering, they said.
Copyright © 2021 scienceboard.net